title: [5-year experience with BCG immunoprophylaxis in superficial bladder cancer].
abstract: Our 5-year experience with BCG in the tumor stage pTis, pTa and pT1, G I-II shows a lasting remission of 88.5% (73%) in 78 (26) patients treated with BCG preparation Pasteur (Connaught) after transurethral resection. A complete remission in patients with carcinoma in situ (12 patients) could be found in 92%. The local and systemic side-effects, which are of limited duration, are tolerable, well treatable and fully reversible.
authors.affiliation: St. Agnes Hospital Urológiai és Gyermekurológiai Osztály, Bocholt.
authors.forename: I
authors.initials: I
authors.lastname: Romics
authors.forename: D
authors.initials: D
authors.lastname: Bach
authors.forename: C
authors.initials: C
authors.lastname: Rüssel
mesh_terms: D000912:Antibodies, Neoplasm / Q000276:immunology; D000951:Antigens, Neoplasm / Q000276:immunology; D001500:BCG Vaccine / Q000008:administration & dosage*; D006801:Humans; D007167:Immunotherapy; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control; D009367:Neoplasm Staging; D014463:Ultrasonography; D001749:Urinary Bladder Neoplasms / Q000000981:diagnostic imaging / Q000276:immunology* / Q000473:pathology / Q000628:therapy
chemical_list: D000912:Antibodies, Neoplasm; D000951:Antigens, Neoplasm; D001500:BCG Vaccine
vernacular_title: Otéves tapasztalataink BCG immunprofilaxissal felületes hólyagdaganatos betegekben.